Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 3/20 | 0.93 |
| ▸ | CYP3A4 | P08684 | 14/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 14/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
| ▸ | POLA1 | P09884 | 1/20 | 0.51 |
| ▸ | POLG | P54098 | 1/20 | 0.51 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17214384 | 1.00 | FAP (0.93) | FAPCYP3A4CYP2D6ABCB11POLA1 | |
| Tenofovir Disoproxil SCHEMBL18907027 | 0.96 | FAP (1.00) | FAPCYP3A4CYP2D6ABCB11POLA1 | |
| Tenofovir Disoproxil SCHEMBL29376425 | 0.96 | FAP (1.00) | FAPCYP3A4CYP2D6ABCB11POLA1 | |
| Tenofovir Disoproxil SCHEMBL497677 | 0.96 | FAP (1.00) | FAPCYP3A4CYP2D6ABCB11POLA1 | |
| Tenofovir Disoproxil SCHEMBL52793 | 0.96 | FAP (1.00) | FAPCYP3A4CYP2D6ABCB11POLA1 | |
| Tenofovir Disoproxil SCHEMBL20421896 | 0.96 | FAP (0.95) | FAPCYP3A4CYP2D6ABCB11POLA1 | |
| Tenofovir Disoproxil SCHEMBL983652 | 0.96 | FAP (0.95) | FAPCYP3A4CYP2D6ABCB11POLA1 | |
| Tenofovir Disoproxil SCHEMBL19031793 | 0.96 | FAP (0.98) | FAPCYP3A4CYP2D6ABCB11POLA1 | |
| Tenofovir Disoproxil SCHEMBL15241296 | 0.95 | FAP (0.96) | FAPCYP3A4CYP2D6 | |
| Tenofovir Disoproxil SCHEMBL16628582 | 0.94 | FAP (0.92) | FAPCYP3A4CYP2D6ABCB11POLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160184332-A1 | MEDICAMENT COMPRISING A PHARMACEUTICAL COMBINATION OF DRUGS | RATIOPHARM GMBH (DE) | 2016-06-30 | — | — | US | disclosed |
| EP-3033084-A1 | MEDICAMENT COMPRISING A PHARMACEUTICAL COMBINATION OF DOLUTEGRAVIR, EMTRICITABINE AND TENOFOVIR | ratiopharm GmbH (DE) | 2016-06-22 | — | — | EP | disclosed |
| WO-2015022351-A1 | MEDICAMENT COMPRISING A PHARMACEUTICAL COMBINATION OF DOLUTEGRAVIR, EMTRICITABINE AND TENOFOVIR | RATIOPHARM GMBH (DE) | 2015-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160184332-A1 | MEDICAMENT COMPRISING A PHARMACEUTICAL COMBINATION OF DRUGS | TYMP, TYMS, ABCB1 | FAP 735/4885CYP3A4 30/4885CYP2D6 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.